At DIVINCELL we create the next-generation RNA therapeutics by combining engineered RNA with precision-designed targeting peptides—delivering breakthrough treatments that attack cancer, autoimmune, and genetic diseases at their source
AANASTRA and DIVINCELL SAS are sister BioPharmaceutical companies, specializing in the development of unique and innovative solutions for targeted RNA therapeutic delivery in the treatment of cancers and genetic diseases
At DIVINCELL we create the next-generation RNA therapeutics by combining engineered RNA with precision-designed targeting peptides—delivering breakthrough treatments that attack cancer, autoimmune, and genetic diseases at their source
DIVINCELL’s Beakthrough Strategies Driving Next-Gen Therapies
Tumor Suppressor Rescue (TSG-RESCUE™): Restoring key tumor suppressors (p53) in cancers driven by loss-of-function mutations—addressing over 400,000 new U.S. cases annually, with no effective options today.
In Vivo CAR-T (PEP-CAR™): Transforming T cells within the body—revolutionizing anti-CD19 CAR-T therapy for blood cancers and autoimmune disease, minimizing toxicity and complexity for well over 100,000 individuals with cancer and over a million individuals with autoimmune disease every year.
Oncogene Editing/Deletion (ONCOEDIT™): Targeted in vivo deletion or silencing of oncogene mutations (KRAS G12D/V)—directly addressing over 110,000 new U.S. cases annually and overcoming drug resistance.
Precision RNA Delivery With Proprietary Peptide Technology
DIVINCELL harnesses engineered RNA molecules and proprietary targeting peptides (PEP-NP™ platform) to create groundbreaking therapies for cancer, autoimmune, and genetic diseases—enabling safe, repeated, and highly selective in vivo delivery of RNA agents.
Overcoming the Delivery Barrier
Unlike viral and lipid systems, our versatile PEP-NP™ technology surmounts the greatest challenge in RNA therapeutics: precise and safe systemic in vivo targeting and efficient cellular release—enabling a new era of programmable molecular medicine.
Founded by Pioneers, Built for Impact
DIVINCELL was founded by industry and research leaders, Dr. Neil Desai (Abraxis, Celgene, Aadi Bioscience) – pioneer of albumin-based drug delivery, and Dr. Gilles Divita (Max Planck Institute, Scripps Research, CNRS) —pioneer of peptide-driven oligonucleotide delivery.
Discover how DIVINCELL is setting the new standard in RNA delivery and disease targeting. Learn More
